Search Tag: ATTR-CM Study
2024 30 Aug
Vutrisiran significantly reduced mortality, cardiovascular events, and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented today in a Hot Line session at ESC Congress 2024. ATTR is a progressive, fatal disease characterised by the accumulation...Read more